NUWE
NASDAQNuwellis Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
News · 26 weeks68+25%
2026-03-012026-08-23
Mix3690d
- Other14(39%)
- SEC Filings13(36%)
- Offering3(8%)
- Leadership3(8%)
- Earnings2(6%)
- Insider1(3%)
Latest news
25 items- PRNuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility MedicalMINNEAPOLIS and MADISON, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, and Atrility Medical, Inc, a cardiac medical technology company, today announced that they have entered into a co-promotion and distribution agreement for Atrility’s AtriAmp® device. "AtriAmp is an excellent strategic fit with Nuwellis' growing pediatric and critical care portfolio, serving many of the same hospitals, physicians and care teams that our commercial organization supports today," said Mike McCormick, Nuwellis President and Chief Executive Officer. "This staged agreement is anothe
- SECSEC Form S-3 filed by Nuwellis Inc.S-3 - Nuwellis, Inc. (0001506492) (Filer)
- SECNuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form 10-Q filed by Nuwellis Inc.10-Q - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross MarginRecent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026. Second Quarter Results and Recent Highlights: Net sales were $2.0 million in the second quarter, a 14% increase compared with the prior-year period; U.S. revenue increased 17%Net sales for the first six months of 2026 were $4.4 million, a 20% increase compared with the prior-year
- PRNuwellis Accelerates Digital Transformation of the Aquadex® Platform with EHR Connectivity and Enhanced User InterfaceMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced a digital transformation program designed to position the Aquadex SmartFlow® System as a connected extracorporeal therapy platform for the modern intensive care environment. The program includes integration through Philips Capsule™ medical device interoperability technology and development of a next-generation tablet-based user interface. Together, these enhancements are expected to improve clinical workflow, strengthen interoperability with hospital information systems, and establish the digita
- PRNuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D EngineerMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a proven track record of advancing innovative products from concept through commercial launch. As Principal R&D Engineer, Brady joins Nuwellis’ research and development team to advance its existing and new product development programs. "Dale's experience developing inno
- PRNuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care ApplicationsMINNEAPOLIS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced strategic development initiatives to expand the capabilities of its Aquadex SmartFlow® System into a broader extracorporeal therapy platform. The program is intended to enhance the system's operating parameters by supporting higher blood flow rates, expanded operating pressure ranges, and broader compatibility with advanced extracorporeal therapies, creating the foundation for future therapeutic applications beyond ultrafiltration. This strategic initiative is intended to expand the Company's l
- SECNuwellis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Nuwellis, Inc. (0001506492) (Filer)
- SECSEC Form 424B5 filed by Nuwellis Inc.424B5 - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common stock at a price of $2.59 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Nuwellis also received approximately $3.1 Million in gross proceeds from the exercise of previously issued warrants which were issued in connection with the Company’s Ju
- PRNuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration TherapyMINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the acceptance of a new single-center retrospective study in Frontiers in Pediatrics, a multi-disciplinary peer-reviewed journal that addresses challenges in pediatric patient care and child health, demonstrating that epoprostenol may serve as a safe and feasible alternative anticoagulant during Aquadex therapy in critically ill pediatric patients. The study, "Epoprostenol as an Alternative Anticoagulant for Pediatric Aquadex Therapy: A Safe and Feasible Option," reports the first documented use of ep
- PRNuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in WisconsinMINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion into Wisconsin with the installation of its first Aquadex SmartFlow® systems at a leading pediatric healthcare institution. The installation further expands the Company's growing presence in pediatric critical care at one of the region's premier academic medical centers. "Establishing our first pediatric program in Wisconsin reflects the continued momentum of our pediatric growth and increasing clinical adoption of our Aquadex therapy and entry into a key market facilitating continued g
- PRNuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit GrowthCompany expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuwellis to report second quarter 2026 financial results on August 13 MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced unaudited preliminary results for its second quarter ended June 30, 2026, with revenue year-over-year growth of 14% for the second quarter of 2026 and 20% for the first six months of 2026. Management expects to report its financial
- SECNuwellis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal TherapiesMINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,678,592, covering the company’s Dual Lumen Catheter, a novel peripheral dual-lumen catheter designed for use with extracorporeal therapies, including ultrafiltration, dialysis, and continuous renal replacement therapy (CRRT) modalities. The patent was issued on July 14, 2026. It further expands Nuwellis' intellectual property portfolio and supports the Company's broader strategy of advancing differentiated technologies acr
- SECSEC Form DEF 14A filed by Nuwellis Inc.DEF 14A - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its participation in the KidneyBee Summit 2026, taking place July 14-16, 2026, at Children's Hospital Colorado in Aurora, Colorado. As part of its participation, Nuwellis will engage with conference attendees to discuss the role of precise fluid management in pediatric patients with acute kidney injury, cardiorenal conditions, and fluid overload. The Company will highlight the Aquadex SmartFlow® System, which enables controlled, predictable fluid removal and is increasingly being utilized at leading p
- INSIDERSEC Form 3 filed by new insider Mccormick Michael Kendrick3 - Nuwellis, Inc. (0001506492) (Issuer)
- SECSEC Form PRE 14A filed by Nuwellis Inc.PRE 14A - Nuwellis, Inc. (0001506492) (Filer)
- PRNuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary of its support of the annual conference for the Pediatric Cardiac Critical Care Consortium (PC4), an alliance aiming to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease. Over the past five years, Nuwellis has collaborated with leading pediatric cardiac critical care institutions to support clinician education, scientific exchange, and awareness of fluid management strategies in critically ill children. Through these efforts
- PRNuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® InstallationsMINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion in Michigan with the installation of three Aquadex SmartFlow® systems at a leading pediatric healthcare provider. This represents Nuwellis’ first pediatric program in the state of Michigan and further expands the Company’s growing presence in pediatric critical care into a significant healthcare market. "Adding our first pediatric program in Michigan advances our strategy to expand Aquadex adoption in pediatric care," said Nuwellis’ Incoming CEO Mike McCormick. "Leading pediatric center
- PRIncoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to ShareholdersMINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and outlines strategic priorities in a Letter to Shareholders from newly appointed CEO, Mike McCormick. Dear Valued Shareholders, Recently we announced an important leadership transition for Nuwellis. Effective June 30, 2026, I will assume the role of Chief Executive Officer, while John Erb will transition from his executive responsibilities and continue as Chairman of the Board. We embark on this leadership transition with growing commercial momentum, improving margins, and a streng
- PRNuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education SummitMINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the clinical utility of its Aquadex SmartFlow® system at the 4th annual Critical Care Cardiology Education Summit (CCCES), hosted by the University of Minnesota. As part of the conference's skills-based curriculum, conference instructors conducted focused Aquadex training sessions that provided participants with practical experience using the Company's ultrafiltration technology. More than 280 physicians completed hands-on Aquadex training during the event, representing one of the largest concentrat
- PRNuwellis Appoints Mike McCormick as Chief Executive OfficerMINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the appointment of Mike McCormick as Chief Executive Officer, effective June 30, 2026. John Erb, who currently serves as President, CEO, and Chairman of the Board, will transition from his executive leadership role and continue serving as Chairman of the Board. "Mike brings an exceptional combination of operational leadership, commercial expertise, and strategic vision," said Erb. "His deep understanding of the medical device industry and proven track record of building and scaling innovative healthc
NUWE FAQ
6 questionsWhat does Nuwellis Inc. do?
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria...Where does NUWE stock trade?
Nuwellis Inc. (NUWE) is listed on NASDAQ.What sector and industry is NUWE in?
Nuwellis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about NUWE?
Nuwellis Inc. has had 1 recent analyst action on file. The most recent action was from ROTH MKM: Buy with a $1700.00 price target on 2024-07-29. Recent price targets cluster around $1700.00.What companies are similar to NUWE?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare NUWE side-by-side with any of them on Quantisnow.How can I track NUWE on Quantisnow?
Quantisnow aggregates Nuwellis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUWE to receive live email and push alerts on every new disclosure.